Argus upgraded Integra LifeSciences (IART) to Buy from Hold.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences Reports Mixed Earnings Amid Challenges
- Sell Rating on Integra Lifesciences Amidst Uncertain Growth and Leadership Transition
- Integra Lifesciences Faces Supply Chain Challenges and Conservative Outlook, Leading to Sell Rating
- Optimistic Growth Outlook for Integra LifeSciences Amidst Transitional Phase and Strategic Initiatives
- Integra LifeSciences Reports Strong Q4 2024 Growth